Healthcare professionals treating conditions such as peripheral neuropathy, wound ulcers, or radiation dermatitis now have fresh, evidence-based guidance on the use of photobiomodulation (PBM) therapy. A new expert consensus provides clinicians in the United States with practical recommendations on how to safely and effectively integrate PBM into patient care.
Photobiomodulation, often referred to as low-level laser therapy or red light therapy, uses specific wavelengths of light to stimulate tissue repair and reduce inflammation. While its use has grown across medical and aesthetic settings, uncertainty has lingered about its safety and best applications—until now.
An international multidisciplinary panel of 21 experts came together to address this gap. Following a systematic review of studies indexed in Embase and MEDLINE, the panel crafted guidelines through a structured Delphi consensus process. This involved two rounds of surveys and consensus meetings to ensure unanimity among panelists.
The resulting clinical recommendations confirm that PBM is a safe non-invasive option for adult patients. Critically, the panel affirmed that red light PBM does not cause DNA damage, easing concerns about its long-term safety. The evidence also highlights PBM’s efficacy in treating a range of conditions: peripheral neuropathy, androgenic alopecia, wound ulcers from various causes, decubitus ulcers, diabetic foot ulcer pain, and acute radiation dermatitis.
For healthcare providers, this consensus offers a robust framework to inform decision-making, particularly in areas where traditional treatments may fall short or where patients seek non-pharmacologic options. While this guideline marks a significant milestone, the expert panel calls for ongoing research to expand understanding of PBM’s potential in both medical and aesthetic applications.
With these recommendations, clinicians can confidently explore PBM as part of a broader care strategy, knowing they are guided by the latest evidence.
Reference: Maghfour J et al. Evidence-Based Consensus on the clinical application of Photobiomodulation. J Am Acad Dermatol. 2025:S0190-9622(25)00659-0.
